Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $19000.0.

  • Regenxbio's Other Non Operating Income fell 2400.0% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year increase of 39600.0%. This contributed to the annual value of $174000.0 for FY2024, which is 59600.0% up from last year.
  • Per Regenxbio's latest filing, its Other Non Operating Income stood at $19000.0 for Q3 2025, which was down 2400.0% from $21000.0 recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Other Non Operating Income registered a high of $554000.0 during Q2 2021, and its lowest value of -$141000.0 during Q4 2023.
  • For the 5-year period, Regenxbio's Other Non Operating Income averaged around $69736.8, with its median value being $37000.0 (2024).
  • As far as peak fluctuations go, Regenxbio's Other Non Operating Income skyrocketed by 30526.32% in 2022, and later tumbled by 28311.69% in 2023.
  • Quarter analysis of 5 years shows Regenxbio's Other Non Operating Income stood at $19000.0 in 2021, then soared by 305.26% to $77000.0 in 2022, then crashed by 283.12% to -$141000.0 in 2023, then surged by 158.87% to $83000.0 in 2024, then plummeted by 77.11% to $19000.0 in 2025.
  • Its last three reported values are $19000.0 in Q3 2025, $21000.0 for Q2 2025, and $25000.0 during Q1 2025.